Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Seems Safe

Long-term mortality and cardiac events were low up to 15 years after ablation.

Although most studies have demonstrated the benefits of alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM), few data exist on long-term safety, and this has limited its application, particularly among relatively young patients. In a large, single-center study, German investigators report on the long-term outcomes of echocardiography-guided ASA in 952 patients (mean age, 56; age range, 15–82; 59% men) treated between 2000 and 2017.

Mean baseline left ventricular gradient was 64 mm Hg at rest and 105 mm Hg after Valsalva maneuver. Average alcohol injection was 2.1 cc, resulting in maximal creatine kinase rise to 872 IU/L. In-hospital complications included death in two patients (0.2%) who developed pulmonary embol…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)